Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Influenza and COVID-19: What does co-existence mean?

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Chotpitayasunondh, T, Fischer, TK, Heraud, J-M, Hurt, AC, Monto, AS, Osterhaus, A, Shu, Y & Tam, JS 2021, 'Influenza and COVID-19: What does co-existence mean?', Influenza and other Respiratory Viruses, vol. 15, no. 3, pp. 407-412. https://doi.org/10.1111/irv.12824

APA

Chotpitayasunondh, T., Fischer, T. K., Heraud, J-M., Hurt, A. C., Monto, A. S., Osterhaus, A., Shu, Y., & Tam, J. S. (2021). Influenza and COVID-19: What does co-existence mean? Influenza and other Respiratory Viruses, 15(3), 407-412. https://doi.org/10.1111/irv.12824

CBE

Chotpitayasunondh T, Fischer TK, Heraud J-M, Hurt AC, Monto AS, Osterhaus A, Shu Y, Tam JS. 2021. Influenza and COVID-19: What does co-existence mean?. Influenza and other Respiratory Viruses. 15(3):407-412. https://doi.org/10.1111/irv.12824

MLA

Vancouver

Chotpitayasunondh T, Fischer TK, Heraud J-M, Hurt AC, Monto AS, Osterhaus A et al. Influenza and COVID-19: What does co-existence mean? Influenza and other Respiratory Viruses. 2021 May;15(3):407-412. https://doi.org/10.1111/irv.12824

Author

Chotpitayasunondh, Tawee ; Fischer, Thea Kølsen ; Heraud, Jean-Michel ; Hurt, Aeron C ; Monto, Arnold S ; Osterhaus, Albert ; Shu, Yuelong ; Tam, John S. / Influenza and COVID-19 : What does co-existence mean?. In: Influenza and other Respiratory Viruses. 2021 ; Vol. 15, No. 3. pp. 407-412.

Bibtex

@article{edc17fb02a8e4748a39cc1f4b63cf0fd,
title = "Influenza and COVID-19: What does co-existence mean?",
abstract = "The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 continues to have a major impact on healthcare and social systems throughout the world. As the clinical and epidemiological features of COVID-19 have many parallels with influenza, it is important to ensure optimal management of both respiratory diseases as we anticipate their continued co-circulation. In particular, there is a need to ensure that effective surveillance and diagnostic capacities are in place to monitor these and other respiratory viruses, as this will underpin decisions on the appropriate clinical management of the respective diseases. As such, we propose a series of key recommendations for stakeholders, public health authorities, primary care physicians and surveillance bodies that will help mitigate the combined risks of concurrent influenza epidemics and the COVID-19 pandemic. We advocate the judicious use of influenza vaccines and antivirals, particularly among groups at high risk of complications, with healthcare workers also considered a priority for vaccination. It is likely that the increased use of emerging technologies such as telemedicine and contact tracing will permanently change our approach to managing infectious disease. The use of these technologies, alongside existing pharmaceutical strategies, will ensure that we achieve a holistic approach to the global public health measures needed to deal with the combined threat of influenza and COVID-19. Ensuring that this approach is optimal will be key as we move from a reactive pandemic response towards preparing for the long-term management of the remarkable clinical burden associated with these respiratory pathogens.",
keywords = "antivirals, clinical management, COVID-19, influenza, SARS-CoV-2, surveillance",
author = "Tawee Chotpitayasunondh and Fischer, {Thea K{\o}lsen} and Jean-Michel Heraud and Hurt, {Aeron C} and Monto, {Arnold S} and Albert Osterhaus and Yuelong Shu and Tam, {John S}",
note = "{\textcopyright} 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.",
year = "2021",
month = may,
doi = "10.1111/irv.12824",
language = "English",
volume = "15",
pages = "407--412",
journal = "Influenza and other Respiratory Viruses",
issn = "1750-2640",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Influenza and COVID-19

T2 - What does co-existence mean?

AU - Chotpitayasunondh, Tawee

AU - Fischer, Thea Kølsen

AU - Heraud, Jean-Michel

AU - Hurt, Aeron C

AU - Monto, Arnold S

AU - Osterhaus, Albert

AU - Shu, Yuelong

AU - Tam, John S

N1 - © 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

PY - 2021/5

Y1 - 2021/5

N2 - The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 continues to have a major impact on healthcare and social systems throughout the world. As the clinical and epidemiological features of COVID-19 have many parallels with influenza, it is important to ensure optimal management of both respiratory diseases as we anticipate their continued co-circulation. In particular, there is a need to ensure that effective surveillance and diagnostic capacities are in place to monitor these and other respiratory viruses, as this will underpin decisions on the appropriate clinical management of the respective diseases. As such, we propose a series of key recommendations for stakeholders, public health authorities, primary care physicians and surveillance bodies that will help mitigate the combined risks of concurrent influenza epidemics and the COVID-19 pandemic. We advocate the judicious use of influenza vaccines and antivirals, particularly among groups at high risk of complications, with healthcare workers also considered a priority for vaccination. It is likely that the increased use of emerging technologies such as telemedicine and contact tracing will permanently change our approach to managing infectious disease. The use of these technologies, alongside existing pharmaceutical strategies, will ensure that we achieve a holistic approach to the global public health measures needed to deal with the combined threat of influenza and COVID-19. Ensuring that this approach is optimal will be key as we move from a reactive pandemic response towards preparing for the long-term management of the remarkable clinical burden associated with these respiratory pathogens.

AB - The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 continues to have a major impact on healthcare and social systems throughout the world. As the clinical and epidemiological features of COVID-19 have many parallels with influenza, it is important to ensure optimal management of both respiratory diseases as we anticipate their continued co-circulation. In particular, there is a need to ensure that effective surveillance and diagnostic capacities are in place to monitor these and other respiratory viruses, as this will underpin decisions on the appropriate clinical management of the respective diseases. As such, we propose a series of key recommendations for stakeholders, public health authorities, primary care physicians and surveillance bodies that will help mitigate the combined risks of concurrent influenza epidemics and the COVID-19 pandemic. We advocate the judicious use of influenza vaccines and antivirals, particularly among groups at high risk of complications, with healthcare workers also considered a priority for vaccination. It is likely that the increased use of emerging technologies such as telemedicine and contact tracing will permanently change our approach to managing infectious disease. The use of these technologies, alongside existing pharmaceutical strategies, will ensure that we achieve a holistic approach to the global public health measures needed to deal with the combined threat of influenza and COVID-19. Ensuring that this approach is optimal will be key as we move from a reactive pandemic response towards preparing for the long-term management of the remarkable clinical burden associated with these respiratory pathogens.

KW - antivirals

KW - clinical management

KW - COVID-19

KW - influenza

KW - SARS-CoV-2

KW - surveillance

UR - http://www.scopus.com/inward/record.url?scp=85094682775&partnerID=8YFLogxK

U2 - 10.1111/irv.12824

DO - 10.1111/irv.12824

M3 - Review

C2 - 33128444

VL - 15

SP - 407

EP - 412

JO - Influenza and other Respiratory Viruses

JF - Influenza and other Respiratory Viruses

SN - 1750-2640

IS - 3

ER -

ID: 61339266